Covered recipient · General Payments record
SASHI K MAKAM
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$6,977.79
186 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $4,637.79 | 185 |
| Consulting Fee | $2,340.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $2,564.45 | 16 |
| AstraZeneca Pharmaceuticals LP | $884.14 | 10 |
| Amgen Inc. | $347.11 | 20 |
| Lilly USA, LLC | $323.89 | 20 |
| GlaxoSmithKline, LLC. | $316.63 | 9 |
| Bayer Healthcare Pharmaceuticals Inc. | $302.31 | 15 |
| Novo Nordisk Inc | $270.82 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $260.36 | 10 |
| Novartis Pharmaceuticals Corporation | $213.11 | 9 |
| Exact Sciences Corporation | $192.10 | 8 |
| Antares Pharma, Inc. | $168.92 | 12 |
| ABBVIE INC. | $155.42 | 8 |
| Otsuka America Pharmaceutical, Inc. | $147.20 | 2 |
| Abbott Laboratories | $143.91 | 9 |
| SANOFI-AVENTIS U.S. LLC | $125.00 | 1 |
| Viatris Specialty LLC | $125.00 | 1 |
| Merck Sharp & Dohme LLC | $97.86 | 3 |
| Insulet Corporation | $64.98 | 3 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $57.05 | 3 |
| Eisai Inc. | $50.61 | 2 |
| Corcept Therapeutics | $44.36 | 2 |
| Medtronic, Inc. | $35.11 | 2 |
| GENZYME CORPORATION | $32.66 | 2 |
| Phathom Pharmaceuticals, Inc. | $20.42 | 1 |
| Almatica Pharma LLC | $17.82 | 1 |
| Ardelyx, Inc. | $16.55 | 1 |
Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SASHI K MAKAM
NPI 1861494908 · CMS profile ID 356994
Allopathic & Osteopathic Physicians / Internal Medicine
NEW WINDSOR, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1861494908?year=2025&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SASHI K MAKAM, NPI 1861494908, CMS profile ID 356994. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861494908?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). SASHI K MAKAM, NPI 1861494908, CMS profile ID 356994. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861494908?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- SASHI K MAKAM, NPI 1861494908, CMS profile ID 356994, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1861494908?year=2025&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
186 matching records · $6,977.79 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–186 of 186.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $20.49 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228556444 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $25.49 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225635996 | CMS |
| PFIZER INC. | $21.31 | 03/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231424837 | CMS |
| Lilly USA, LLC | $19.95 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186894943 | CMS |
| Lilly USA, LLC | $4.19 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186918850 | CMS |
| Amgen Inc. | $15.47 | 03/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228556454 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10.65 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222771217 | CMS |
| Abbott Laboratories | $17.38 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240884145 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.79 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222771215 | CMS |
| Novo Nordisk Inc | $11.64 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189044431 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $19.04 | 03/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225635980 | CMS |
| Novo Nordisk Inc | $14.34 | 02/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188265036 | CMS |
| GlaxoSmithKline, LLC. | $18.82 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190526232 | CMS |
| Phathom Pharmaceuticals, Inc. | $20.42 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1219381405 | CMS |
| Exact Sciences Corporation | $27.53 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235590731 | CMS |
| PFIZER INC. | $22.99 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231641219 | CMS |
| Novartis Pharmaceuticals Corporation | $20.27 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200721762 | CMS |
| Lilly USA, LLC | $14.53 | 02/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186880941 | CMS |
| Novartis Pharmaceuticals Corporation | $28.84 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200721760 | CMS |
| Merck Sharp & Dohme LLC | $24.41 | 02/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238228514 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $17.94 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225635976 | CMS |
| ABBVIE INC. | $26.32 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202352195 | CMS |
| Abbott Laboratories | $18.92 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240883561 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12.13 | 02/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222771213 | CMS |
| Exact Sciences Corporation | $25.04 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235590727 | CMS |
| AstraZeneca Pharmaceuticals LP | $90.34 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214800086 | CMS |
| GlaxoSmithKline, LLC. | $20.77 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190826018 | CMS |
| GENZYME CORPORATION | $14.64 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233294592 | CMS |
| PFIZER INC. | $15.35 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229241789 | CMS |
| Novo Nordisk Inc | $22.62 | 01/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189133138 | CMS |
| Amgen Inc. | $15.24 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228556450 | CMS |
| Lilly USA, LLC | $24.31 | 01/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186885981 | CMS |
| Novo Nordisk Inc | $13.43 | 01/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188239293 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $18.53 | 01/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225635992 | CMS |
| PFIZER INC. | $0.47 | 01/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231351474 | CMS |
| PFIZER INC. | $21.91 | 01/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231423795 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,597,587.44 | 86 |
| PY2024 | Recipient | $4,915.80 | 2 |
| PY2024 | Principal investigator | $1,024,395.34 | 96 |
| PY2023 | Recipient | $8,918.76 | 3 |
| PY2023 | Principal investigator | $1,226,252.03 | 124 |
| PY2022 | Principal investigator | $219,103.85 | 166 |
| PY2021 | Principal investigator | $508,775.89 | 397 |
| PY2020 | Principal investigator | $863,832.62 | 334 |
| PY2019 | Principal investigator | $698,327.86 | 243 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
86 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,102.20 | 12/31/2025 | Non-covered Recipient Entity Mid Hudson Medical Research | A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-na ve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease | No dispute reported | 06/30/2026 | 1232934094 |
| Principal investigator 1 | PFIZER INC. | $905.85 | 12/31/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228745730 |
| Principal investigator 1 | Genentech, Inc. | $13,925.05 | 12/24/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625444 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.18 | 12/24/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192154960 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $828.90 | 12/24/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158118 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,408.07 | 12/24/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158123 |
| Principal investigator 1 | PFIZER INC. | $10,345.73 | 12/17/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228723746 |
| Principal investigator 1 | PFIZER INC. | $42,956.33 | 12/16/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228731949 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,315.96 | 12/11/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192154979 |
| Principal investigator 1 | Genentech, Inc. | $1,650.00 | 12/03/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625448 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,958.87 | 12/01/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508610 |
| Principal investigator 1 | PFIZER INC. | $7,189.92 | 11/27/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228739311 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $481.65 | 11/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043770 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $12,500.00 | 11/05/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508613 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,000.00 | 11/05/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508617 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 11/05/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625439 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,950.00 | 11/03/2025 | Non-covered Recipient Entity Mid Hudson Medical Research, Pllc | A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease | No dispute reported | 06/30/2026 | 1235995701 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,631.20 | 10/23/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192154957 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,250.00 | 10/22/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192158037 |
| Principal investigator 1 | Celgene Corporation | $14,500.00 | 10/15/2025 | Non-covered Recipient Entity Mid Hudson Medical Research, Pllc | A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease | No dispute reported | 06/30/2026 | 1222305246 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,200.00 | 10/15/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192158024 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,967.00 | 10/14/2025 | Non-covered Recipient Entity Mid Hudson Medical Research | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226137155 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,925.00 | 10/10/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192158029 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,000.00 | 10/10/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192158033 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $761.00 | 10/09/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043768 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,615.19 | 09/24/2025 | Non-covered Recipient Entity Mid Hudson Medical Research, Pllc | A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease | No dispute reported | 06/30/2026 | 1235995697 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,852.69 | 09/05/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH, PLLC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185551235 |
| Principal investigator 1 | Verona Pharma, Inc. | $10,000.00 | 09/03/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RSRCH. PLLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891671 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,852.00 | 09/03/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RSRCH. PLLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891673 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,211.95 | 08/19/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043766 |
| Principal investigator 1 | PFIZER INC. | $1,837.36 | 08/13/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228768001 |
| Principal investigator 1 | PFIZER INC. | $762.76 | 08/06/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228760606 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $68.20 | 08/05/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043904 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $481.65 | 07/24/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043764 |
| Principal investigator 1 | PFIZER INC. | $1,287.23 | 07/23/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228781761 |
| Principal investigator 1 | PFIZER INC. | $9,060.59 | 07/11/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228789929 |
| Principal investigator 1 | Genentech, Inc. | $6,300.00 | 07/02/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625436 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $29,675.91 | 06/25/2025 | Non-covered Recipient Entity Mid Hudson Medical Research, Pllc | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease | No dispute reported | 06/30/2026 | 1235995699 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,820.75 | 06/24/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043762 |
| Principal investigator 1 | PFIZER INC. | $26,538.48 | 06/21/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228793616 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $68.20 | 06/19/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043902 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,600.00 | 06/11/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH, PLLC | A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol | No dispute reported | 06/30/2026 | 1185551243 |
| Principal investigator 1 | PFIZER INC. | $38,096.43 | 06/06/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228792389 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,250.00 | 06/05/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043760 |
| Principal investigator 1 | Genentech, Inc. | $900.00 | 06/04/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625427 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,251.12 | 05/22/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158101 |
| Principal investigator 1 | Genentech, Inc. | $1,800.00 | 05/09/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625423 |
| Principal investigator 1 | PFIZER INC. | $66,156.20 | 04/29/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228796563 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,193.29 | 04/23/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH, PLLC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190313327 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,657.80 | 04/17/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192154975 |
| Principal investigator 1 | Genentech, Inc. | $900.00 | 04/11/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625432 |
| Principal investigator 1 | PFIZER INC. | $58,181.80 | 04/10/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228780252 |
| Principal investigator 1 | PFIZER INC. | $9,788.88 | 04/01/2025 | Non-covered Recipient Entity Mid Hudson Medical Research PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228791006 |
| Principal investigator 1 | Genentech, Inc. | $1,800.00 | 03/21/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625409 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $173.75 | 03/21/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | No dispute reported | 06/30/2026 | 1225335721 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,189.51 | 03/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158115 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,738.45 | 03/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043758 |
| Principal investigator 1 | AstraZeneca UK Limited | $88,966.20 | 03/12/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH, PLLC | A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol | No dispute reported | 06/30/2026 | 1185551245 |
| Principal investigator 1 | Genentech, Inc. | $2,380.00 | 03/05/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625421 |
| Principal investigator 1 | Genentech, Inc. | $2,380.00 | 02/21/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625390 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/21/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043900 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 02/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192154965 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 02/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192154970 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,550.00 | 02/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158020 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 02/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158096 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $675.00 | 02/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158127 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 02/20/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158131 |
| Principal investigator 1 | Genentech, Inc. | $1,800.00 | 02/12/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625397 |
| Principal investigator 1 | Genentech, Inc. | $8,160.00 | 02/05/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625413 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,848.85 | 01/31/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH, PLLC | A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi | No dispute reported | 06/30/2026 | 1185551237 |
| Principal investigator 1 | Eli Lilly and Company | $1,033.03 | 01/31/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | No dispute reported | 06/30/2026 | 1187884958 |
| Principal investigator 1 | Eli Lilly and Company | $535.00 | 01/31/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187885506 |
| Principal investigator 1 | Eli Lilly and Company | $1,708.45 | 01/31/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187886752 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,384.59 | 01/30/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158105 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,361.92 | 01/30/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192158111 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $60,982.50 | 01/29/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH, PLLC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185551239 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,629.27 | 01/29/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH, PLLC | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185551247 |
| Principal investigator 1 | Eli Lilly and Company | $22,975.00 | 01/28/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187884642 |
| Principal investigator 1 | Eli Lilly and Company | $45,862.68 | 01/27/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187886726 |
| Principal investigator 1 | Genentech, Inc. | $640.00 | 01/22/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625404 |
| Principal investigator 1 | Genentech, Inc. | $320.00 | 01/17/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625401 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,738.45 | 01/16/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244043756 |
| Principal investigator 1 | Genentech, Inc. | $1,020.00 | 01/14/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625394 |
| Principal investigator 1 | Genentech, Inc. | $1,460.00 | 01/13/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211625418 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,375.59 | 01/08/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH, PLLC | A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1185551241 |
| Principal investigator 1 | Eli Lilly and Company | $836,983.21 | 01/07/2025 | Non-covered Recipient Entity MID HUDSON MEDICAL RESEARCH PLLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | No dispute reported | 06/30/2026 | 1187884268 |